In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia Set To Decide On Breast Implant Cancer Link; Dutch Say No To A Ban

Executive Summary

Australian regulators expect to say in a few weeks’ time what action, if any, they will take on breast implants following the ongoing worldwide reports of a link between certain types of product and a rare form of cancer. Meanwhile, authorities in the Netherlands say the implants can stay on the market.

You may also be interested in...



Breast Implant-Makers Now Required To File Individual Reports On Each Adverse Event, FDA Says

The agency is redoubling efforts to warn women about the risks of silicone and saline breast implants after feedback from a recent advisory panel meeting. On 2 May, the regulator said it is requiring manufacturers to file individual Medical Device Reports for each adverse event regarding implants – part of a bigger effort to end its Alternative Summary Reporting Program for all devices.

COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs And Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

Topics

UsernamePublicRestriction

Register

MT125187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel